Skip to content


New report mapping the challenge of type 2 diabetes in Greater Manchester

Find all our latest news, events, media and blogs.


To keep up to date follow the NIHR ARC-GM Twitter account @ARC_GM_

New report mapping the challenge of type 2 diabetes in Greater Manchester

A new report has been published summarising new research findings and insights on the impact of type 2 diabetes in Greater Manchester.

This follows a collaborative project with industry, academic and healthcare partners, and highlights how local ethnic minority communities and an increasing number of younger people within the city region are affected by type 2 diabetes.

The report has been written, funded and distributed by Novo Nordisk, in collaboration with ourselves (NIHR ARC-GM), Health Innovation Manchester, The University of Manchester, The University of Salford, Manchester Metropolitan University, and the British Muslim Heritage Centre.


As part of the Cities Changing Diabetes (CCD) Manchester programme, this work specifically looks at the nature of type 2 diabetes in Greater Manchester, the existing initiatives that address these challenges, and how to engage the community to help develop action to address the impact of the condition. The overall aim being to provide helpful insights and recommendations for partners from across Greater Manchester, both health and care organisations, public health colleagues and wider community organisations, about how they can collectively work together to help reduce the impact of type 2 diabetes in Greater Manchester.

Greater Manchester hasjoined cities such as Copenhagen, Rome, and Shanghai as part of the Cities Changing Diabetes partnership, and was named as the twenty-first global city to join Cities Changing Diabetes in 2019.

Hare are some of the key findings and insights ftom the new published report from the Cities Changing Diabetes Manchester programme:


  • Those aged under 40, particularly men of white ethnic origin and men and individuals living in the most deprived neighbourhoods are most likely to experience under-diagnosis of type 2 diabetes.
  • GP practices within Greater Manchester whose diabetes populations are younger tend to perform less well than others in terms of delivery of care and the meeting of treatment targets for their diabetes patients.
  • Those aged under 40 with type 2 diabetes feel that existing care and support is not tailored to their needs, with a sense that education courses to support self-management of their condition do not reflect their lifestyles and seem to be aimed more at older people living with the condition.


Dr Tracey Vell MBE, Clinical Director at Health Innovation Manchester, said:


“The impact of the COVID-19 pandemic has highlighted how vital programmes such as Cities Changing Diabetes are to maintaining and improving the health of our population. During the early stages of the pandemic those living with diabetes and obesity faced a disproportionate risk of poorer outcomes, highlighting the ongoing risk of health complications associated with type 2 diabetes.


“We hope that the work undertaken during the Cities Changing Diabetes programme will further support the health and care system in Greater Manchester, as well as our research partners, to collectively tackle type 2 diabetes and reduce its impact within the city region. We at Health Innovation Manchester are enthusiastic about how this work and ongoing collaborations can develop further innovations and research to support type 2 diabetes prevention and care, with a person-centred approach, within Greater Manchester.”


Pinder Sahota, General Manager, Novo Nordisk UK, said:


“Cities are complex environments, where a number of nutritional, demographic, social, cultural and economic factors can affect people’s health. The increase in type 2 diabetes that Manchester and other cities are seeing is not inevitable, and I believe we can change its trajectory if we act now.


This work with Health Innovation Manchester and other partners through the Cities Changing Diabetes programme, will help the city region to continue its mission to tackle the societal and personal impact of this chronic condition.”

Dr Naresh Kanumilli, Diabetes Clinical Lead at Greater Manchester and Eastern Cheshire Strategic Clinical Network, said:


“As a GP working within a large general practice in South Manchester I have seen the impact that type 2 diabetes can have on the lives of those affected by the condition, but I strongly feel that we as health care providers have a lot more to learn and understand about the needs of people living with type 2 diabetes in our region. This is a priority for me.


“The Cities Changing Diabetes programme provides us with a unique opportunity to do this. I was delighted to work alongside Health Innovation Manchester to secure Greater Manchester’s involvement in the global programme, with the support of Novo Nordisk. Bringing different local partners together around the table, including those directly affected by type 2 diabetes, in a collective endeavour to address the impact of this chronic condition will be key going forward as we work to improve the health of our population.”


The full report, titled 'Mapping the challenge of type 2 diabetes in Greater Manchester' can be accessed from here


For further information about our invovlement in the Cities Changing Diabetes work please check out the project page on our website here 


Published 13/06/2022